Financial Results, Clinical Trial Initiations, Drug Designations, Appointments, and Study Results - Research Reports on Cubist, Jazz, InterMune, NPS Pharmaceuticals and ACADIA

NEW YORK, July 30, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), InterMune, Inc. (NASDAQ: ITMN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5256-100free.

--
Cubist Pharmaceuticals Inc. Research Reports
On July 22, 2014, Cubist Pharmaceuticals, Inc. (Cubist) reported its Q2 2014 financial results with total net revenues of $294.4 million, up 13.8% YoY. GAAP operating income totaled $42.2 million compared to $28.1 million in Q2 2013. GAAP diluted EPS was $0.30 compared to $0.23 in Q2 2013. "This was another exciting quarter for Cubist in which we launched an important new antibiotic treatment and made significant progress advancing another key pipeline program," said Michael Bonney, CEO of Cubist. "The FDA's approval of SIVEXTRO™, and acceptance of our New Drug Application for our potential blockbuster, ceftolozane/tazobactam, reinforces our position as the worldwide leader in the research, development, and commercialization of antibiotics with activity against a range of resistant and problematic pathogens." As of June 30, 2014, Cubist had $643.5 million in cash, cash equivalents and investments. The full research reports on Cubist are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/CBST/report.pdf

--
Jazz Pharmaceuticals Public Limited Company Research Reports
On July 21, 2014, Jazz Pharmaceuticals Public Limited Company (Jazz) and Concert Pharmaceuticals, Inc. (CNCE) announced the commencement of the first Phase 1 clinical trial of JZP-386, a deuterium-containing analog of sodium oxybate-the active ingredient in Xyrem® (sodium oxybate) oral solution. The Company stated that the trial aims to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JZP-386, and includes Xyrem as an active control. "Initiating this first-in-human Phase 1 study with JZP-386 is an important milestone in our development program and will provide valuable information on the potential benefit of this deuterium-containing analog of sodium oxybate." said Jeffrey Tobias, M.D., Executive Vice President and Chief Medical Officer of Jazz. The full research reports on Jazz are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/JAZZ/report.pdf

--
InterMune, Inc. Research Reports
On July 17, 2014, InterMune, Inc. (InterMune) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to pirfenidone, an investigational treatment for adult patients with idiopathic pulmonary fibrosis (IPF). "The Breakthrough Therapy Designation underscores the significant need to help patients with this irreversible and ultimately fatal disease, particularly as no FDA-approved therapies are currently available," said Dan Welch, Chairman, CEO and President of InterMune. "We are pleased that the FDA recognized the importance of pirfenidone as a potential new therapy for IPF, a disease with great unmet medical need." The Company stated that the designation is reserved for drugs that are intended to treat a serious or life threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The full research reports on InterMune are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/ITMN/report.pdf

--
NPS Pharmaceuticals, Inc. Research Reports
On July 24, 2014, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) announced the results from PARADOX, the most comprehensive research to date analyzing the burden of illness of Hypoparathyroidism, which were published in the journal Endocrine Practice. According to the Company, the results show that a majority of patients with the disorder report experiencing a multitude of physical, emotional and cognitive symptoms that have an impact on both their personal and professional lives. "The results of this landmark research show that patients with Hypoparathyroidism often experience symptoms on a daily basis and that a large percentage of patients continue to experience symptoms despite management with large doses of calcium and vitamin D," said Bart Clarke, MD, associate professor of medicine at Mayo Clinic and lead researcher for PARADOX. Further, the study results suggested that the burden of illness associated with Hypoparathyroidism goes beyond clinical symptoms. The full research reports on NPS Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/NPSP/report.pdf

--
ACADIA Pharmaceuticals Inc. Research Reports
On July 15, 2014, ACADIA Pharmaceuticals, Inc. (ACADIA) announced that Stephen Davis has been appointed as the Company's Executive Vice President, CFO and Chief Business Officer, effective July 15, 2014. "Steve is a highly accomplished industry executive with extensive financial and operational experience, and will be an outstanding addition to our team," said Dr. Uli Hacksell, Ph.D., ACADIA's CEO. "Steve's impressive background and demonstrated leadership skills will be key as we continue to build the corporate infrastructure necessary to support the planned launch of pimavanserin in Parkinson's disease psychosis and seek to maximize the significant opportunities ahead for pimavanserin." The Company stated that Mr. Davis has over 20 years of executive-level experience in the pharmaceutical industry. The full research reports on ACADIA are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/ACAD/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review